Cargando…

Phosphoproteome Profiling of the Receptor Tyrosine Kinase MuSK Identifies Tyrosine Phosphorylation of Rab GTPases

Muscle-specific receptor tyrosine kinase (MuSK) agonist antibodies were developed 2 decades ago to explore the benefits of receptor activation at the neuromuscular junction. Unlike agrin, the endogenous agonist of MuSK, agonist antibodies function independently of its coreceptor low-density lipoprot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Budayeva, Hanna G., Sengupta-Ghosh, Arundhati, Phu, Lilian, Moffat, John G., Ayalon, Gai, Kirkpatrick, Donald S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972003/ https://www.ncbi.nlm.nih.gov/pubmed/35227894 http://dx.doi.org/10.1016/j.mcpro.2022.100221

Ejemplares similares

Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling
por: Otsuka, Kenji, et al.
Publicado: (2015)

Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA)
por: Feng, Zhihua, et al.
Publicado: (2021)

Protein Tyrosine Phosphatase Receptor Type R (PTPRR) Reduces AChR Clustering by Dephosphorylating MuSK
por: Chen, Yanxun, et al.
Publicado: (2022)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
por: Bhaskar, Shalini, et al.
Publicado: (2022)

Endosomal trafficking of the receptor tyrosine kinase MuSK proceeds via clathrin-dependent pathways, Arf6 and actin
por: Luiskandl, Susan, et al.
Publicado: (2013)

The formation of complex acetylcholine receptor clusters requires MuSK kinase activity and structural information from the MuSK extracellular domain
por: Mazhar, Sania, et al.
Publicado: (2012)

MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction
por: Cartaud, Annie, et al.
Publicado: (2004)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
por: Rodolico, Carmelo, et al.
Publicado: (2020)

Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis
por: Kwon, Young Nam, et al.
Publicado: (2022)

Mutations in MUSK causing congenital myasthenic syndrome impair MuSK–Dok-7 interaction
por: Maselli, Ricardo A., et al.
Publicado: (2010)

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity
por: Huijbers, Maartje G., et al.
Publicado: (2019)

Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure
por: Rodríguez Cruz, Pedro M., et al.
Publicado: (2019)

Corrigendum: MuSK Kinase Activity is Modulated By A Serine Phosphorylation Site in The Kinase Loop
por: Camurdanoglu, B. Z., et al.
Publicado: (2016)

Repetitive Nerve Stimulation in MuSK-Antibody-Positive Myasthenia Gravis
por: Kim, Seung Woo, et al.
Publicado: (2017)

MuSK EAMG: Immunological Characterization and Suppression by Induction of Oral Tolerance
por: Reuveni, Debby, et al.
Publicado: (2020)

IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation
por: Cao, Michelangelo, et al.
Publicado: (2023)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
por: Lanfranconi, S., et al.
Publicado: (2011)

A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
por: Ben Ammar, Asma, et al.
Publicado: (2013)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
por: Zhang, Zunwei, et al.
Publicado: (2020)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
por: Huang, Qi, et al.
Publicado: (2022)

Myopathy or Myasthenia Positive for Antibodies Against MuSK, Lrp4, and Titin
por: Finsterer, Josef, et al.
Publicado: (2020)

Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex
por: Xie, Tian, et al.
Publicado: (2023)

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK
por: Lim, Jamie L., et al.
Publicado: (2023)

A novel pathway for MuSK to induce key genes in neuromuscular synapse formation
por: Lacazette, Eric, et al.
Publicado: (2003)

MuSK induces in vivo acetylcholine receptor clusters in a ligand-independent manner
por: Sander, Andreas, et al.
Publicado: (2001)

Temporal and Spatial Requirements of unplugged/MuSK Function during Zebrafish Neuromuscular Development
por: Jing, Lili, et al.
Publicado: (2010)

Correction: A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
por: Ben Ammar, Asma, et al.
Publicado: (2013)

Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody
por: Cantor, Sarah, et al.
Publicado: (2018)

Anti-MuSK-Positive Myasthenic Crisis in a 7-Year-Old Female
por: Matthews, Harrison J., et al.
Publicado: (2017)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
por: Schneider-Gold, Christiane, et al.
Publicado: (2017)

A Neonate With MuSK Congenital Myasthenic Syndrome Presenting With Refractory Respiratory Failure
por: Shen, Yanhua, et al.
Publicado: (2020)

MuSK (Muscle Specific Kinase) Positive Myasthenia: Grave Prognosis or Undue Prejudice?
por: Samal, Priyanka, et al.
Publicado: (2020)

MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation
por: König, Nicole, et al.
Publicado: (2021)

Reply to: Myopathy in Myasthenia Positive for Antibodies Against MuSK, Lrp4, and Titin
por: Yamashita, Rika, et al.
Publicado: (2020)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
por: Bardakov, Sergey N., et al.
Publicado: (2022)

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
por: Vergoossen, Dana L. E., et al.
Publicado: (2021)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oij9dkuoi2872i27db1jns8ie2